16.8 C
New York
Sunday, May 19, 2024
HomeMarkets
Markets

JP Morgan Initiates Bioline RX With Market Outperform

By Insider Scoop
0
8
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Related BLRX
BioLineRx Says Will Present Successful Results of Phase 1/2 Study of Novel Celiac Treatment
Research Underlying BioLineRx's Treatment of Type 1 Diabetes Wins Hebrew University's Kaye Innovation Award

JP Morgan initiated coverage on Bioline RX Ltd (NASDAQ: BLRX) with a Market Outperform rating.

The target price for Bioline RX is set to $5.

Bioline RX shares have dropped 4.17 percent over the past 52 weeks, while the S&P 500 index has gained 7.51 percent in the same period.

Bioline RX shares gained 4.34 percent to $2.16 in pre-market trading.

Latest Ratings for BLRX

Date Firm Action From To
Jun 2015 JP Morgan Initiates Coverage on Market Outperform

View More Analyst Ratings for BLRX
View the Latest Analyst Ratings

Posted-In: JP MorganInitiation Analyst Ratings

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,198FansLike
396,312FollowersFollow
2,300SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x